Open Beta
TREN
MetriLume
TREN

US marketsARQT

SEC-sourced researchBeta

ARQT

Arcutis Biotherapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001787306
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 59,606,000.0000 USD; December 2024: 196,542,000.0000 USD; December 2025: 376,072,000.0000 USD376.1M USD0 USD0December 2023December 2024December 2025
ARQT · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202359,606,000.0000Feb 25, 2026
December 2024196,542,000.0000Feb 25, 2026
December 2025376,072,000.0000Feb 25, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025376,072,000.0000-16,141,000.0000-5,625,000.0000432,973,000.0000243,494,000.0000Feb 25, 2026
December 2024196,542,000.0000-140,039,000.0000-112,158,000.0000348,889,000.0000191,348,000.0000Feb 25, 2026
December 202359,606,000.0000-262,140,000.0000-247,057,000.0000——Feb 25, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

66/100
Profitability41
Growth100
Balance sheet44
Cash generation47
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$376.07MJan 1, 2025 – Dec 31, 2025Feb 25, 202610-K
Previous period revenueRevenues$196.54MJan 1, 2024 – Dec 31, 2024Feb 25, 202610-K
Net incomeNetIncomeLoss-$16.14MJan 1, 2025 – Dec 31, 2025Feb 25, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$5.63MJan 1, 2025 – Dec 31, 2025Feb 25, 202610-K
Total assetsAssets$432.97MDec 31, 2025Feb 25, 202610-K
Total liabilitiesLiabilities$243.49MDec 31, 2025Feb 25, 202610-K

New filings

Explore methodology ↗